VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
Clinical trial NCT01581138 · COMPLETED
Trial details
- NCT number
- NCT01581138
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-01
- Primary completion
- 2013-06-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.